卡那奴单抗治疗单基因自身炎症性疾病的长期安全性与有效性:RELIANCE登记研究的中期分析结果
RELIANCE登记研究中期分析纳入168例接受卡那奴单抗常规治疗的CAPS、FMF、TRAPS或MKD/HIDS患者,至第30个月多数患者疾病活动度为无或轻/中度,约70%患者维持缓解,炎症标志物和患者报告结局持续良好控制;CAPS队列中高于推荐起始剂量的患者严重感染和严重药物不良反应更常见。
要点
- 至第30个月约70%患者维持缓解,多数疾病活动度为无或轻/中度。
- CAPS队列中高于推荐起始剂量者严重感染和严重药物不良反应更常见。
- 合并人群中观察到接受高于推荐起始剂量的趋势。
核心结论
- 本分析数据证实卡那奴单抗治疗CAPS、FMF、TRAPS和MKD/HIDS具有长期安全性和有效性。
研究设计与样本
- RELIANCE为正在进行的非干预性、开放标签、多中心、前瞻性登记研究,评估卡那奴单抗的长期安全性、给药方案和有效性。
- CAPS患者自2017年9月起、FMF/TRAPS/MKD/HIDS患者自2018年6月起入组,纳入接受卡那奴单抗作为常规医疗一部分的儿童(≥2岁)和成人(≥18岁)患者。
- 基线及每6个月评估安全性、卡那奴单抗剂量、疾病活动度和生活质量结局指标,直至研究结束访视。
主要发现
- 截至分析截止日期(2020年12月),共入组168例患者(CAPS 91例、FMF 54例、TRAPS 16例、MKD/HIDS 7例)。
- 85例(50.9%)患者为女性,72例(43.1%)为儿童(<18岁),患者中位年龄为20.0岁(范围2.0-79.0岁)。
- CAPS队列中,接受高于卡那奴单抗推荐起始剂量的患者严重感染和严重药物不良反应更常见。
- 合并人群中观察到接受高于推荐起始剂量的趋势。
- 从基线至第30个月,多数患者医师整体评估为无或轻/中度疾病活动度,约70%患者在卡那奴单抗治疗下维持缓解,比例稳定。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Interim analysis of the RELIANCE registry, an on-going, non-interventional, open-label, multicentre, prospective study evaluating the long-term safety, dosing regimens and effectiveness of canakinumab in patients with cryopyrin-associated periodic syndromes (CAPS), familial Mediterranean fever (FMF), tumour-necrosis factor receptor-associated periodic syndrome (TRAPS) or mevalonate-kinase deficiency (MKD)/hyperimmunoglobulin-D syndrome (HIDS). METHODS: From September 2017 for patients with CAPS, and June 2018 for patients with FMF, TRAPS or MKD/HIDS, the registry enrolled paediatric (aged ≥2 years) and adult patients (aged ≥18 years) receiving canakinumab as part of their routine medical care. Safety, canakinumab dose, disease activity and quality of life outcome measures were evaluated at baseline and every 6 months until end of study visit. RESULTS: At the analysis cut-off date (December 2020), 168 patients (91 CAPS, 54 FMF, 16 TRAPS and 7 MKD/HIDS) were enrolled. 85 (50.9%) patients were female and 72 (43.1%) were children (<18 years). The median patient age was 20.0 years (range 2.0-79.0 years). In the CAPS cohort, serious infections and serious adverse drug-reactions were more common in patients receiving higher than the recommended starting dose (SD) of canakinumab. A trend to receive >SD of canakinumab was observed in the pooled population. The majority of patients were reported as having either absent or mild/moderate disease activity (physician's global assessment) from baseline to Month 30, with a stable proportion of patients (~70%) in remission under canakinumab treatment. Patient-reported disease activity (Visual Analogue Scale (VAS), Autoinflammatory Disease Activity Index), fatigue (VAS); markers of inflammation (C-reactive protein, serum amyloid A and erythrocyte sedimentation rate) remained well-controlled throughout. CONCLUSION: Data from this analysis confirm the long-term safety and effectiveness of canakinumab for the treatment of CAPS, FMF, TRAPS and MKD/HIDS.
引用
- Kuemmerle-Deschner JB, Kallinich T, Henes J, et al. Long-term safety and effectiveness of canakinumab in patients with monogenic autoinflammatory diseases: results from the interim analysis of the RELIANCE registry. RMD Open. 2024. PMID: 38360038. doi:10.1136/rmdopen-2023-003890
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。